Skip to main content
Premium Trial:

Request an Annual Quote

NextGen Enters Gene Synthesis Market After Licensing Gene Oracle's GeneIOS Technology

NEW YORK (GenomeWeb News) – NextGen has entered the gene-synthesis market after licensing Gene Oracle's GeneIOS gene-synthesis products and services, NextGen said today.
 
Under the agreement, NextGen will incorporate the GeneIOS technology into a new generation of ContractExpress products. The company will offer the combined technology as part of its fee-for-service offering.
 
NextGen will also offer GeneIOS as a standalone gene-synthesis product in the gene-to-protein development market.
 
NextGen expects to complete the technology transfer in the current quarter. NextGen will pay Gene Oracle technology transfer fees and ongoing royalty payments from commercial activities involving GeneIOS.
 
Additional details were not disclosed.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.